Glaxosmithkline | GSK - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 538M 2026-03
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Aurora Cannabis CAD 129.98M 16.05M 2025-12
Bausch Health Companies USD 2.04B 42M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Canopy Growth CAD 87.2M 6.22M 2025-12
Corcept Therapeutics USD 214.5M 16.87M 2026-03
Drreddys Laboratories INR 72.94B 4.33B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Glaxosmithkline GBP 9.17B 1.4B 2025-12
J&J USD 17.44B 1.53B 2026-03
Merck USD 18.17B 8.01B 2026-03
Novartis USD 9.29B 507M 2026-03
Pacira USD 172.75M 20.93M 2026-03
Perrigo USD 935.6M 89.6M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Phibro Animal Health USD 361.83M 29.47M 2026-03
Prestige Brands USD 206.12M 5.17M 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
Supernus Pharmaceuticals USD 1.08B 879.06M 2026-03
Takeda JPY 1.11T 85.29B 2026-03
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Zoetis USD 3.23B 1.68B 2026-03